Core Viewpoint - Calidi Biotherapeutics has successfully strengthened its financial position through recent fundraising efforts, allowing the company to terminate its Standby Equity Purchase Agreement, which is seen as a strategic move to enhance shareholder value and focus on clinical goals [1][4]. Financial Position - As of December 31, 2024, Calidi reported an ending cash balance of approximately $9.6 million [1]. - In the fourth quarter of 2024, the company secured $9.5 million in gross proceeds from two public offerings, along with $2.0 million from warrant exercises and $3.1 million from its At-The-Market facility [3]. - A subsequent public offering in January 2025 raised an additional $4.25 million in gross proceeds [3]. Financing Strategy - The termination of the Standby Equity Purchase Agreement (SEPA) was a significant milestone in Calidi's financing strategy, allowing the company to avoid potential stock overhang and focus on operational goals [4]. - The SEPA, which was executed in December 2023, allowed Calidi the option to sell up to $25 million of common stock over three years, but the company did not exercise this option [2]. Clinical Development - Calidi is advancing its innovative virotherapy platforms, with recent milestones including the acceptance of an abstract for its systemic platform at the American Association for Cancer Research Annual Meeting in April 2025 [4]. - The company received IND clearance from the FDA for a Phase 1b/2 trial of CLD-101 targeting high-grade gliomas, with plans to begin patient enrollment in the first quarter of 2025 [4]. Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted antitumor virotherapies using proprietary stem cell-based platforms [5]. - The company's technology aims to enhance the immune system's ability to fight cancer, particularly in high-grade gliomas and solid tumors [5].

Core Insights - Calidi Biotherapeutics has announced the acceptance of its abstract for presentation at the AACR Annual Meeting, highlighting its commitment to advancing systemic enveloped virotherapy for metastatic cancers [1][2] - The proprietary RTNova systemic platform aims to address challenges in treating advanced-stage metastatic cancers by enabling targeted delivery to multiple tumor sites while evading rapid elimination by the immune system [2][3] - The company is also preparing to submit an abstract for the ASCO Annual Meeting in June 2025, focusing on selecting a lead clinical candidate for RTNova [4] Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company that utilizes proprietary technology to enhance the immune system's ability to combat cancer [5] - The company employs novel stem cell-based platforms that can carry oncolytic viruses for various oncology indications, including high-grade gliomas and solid tumors [5] - Calidi's dual approach includes both systemic enveloped virotherapies and localized cell-based virotherapies, aiming to treat or prevent metastatic disease [5]

Company Overview - Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing targeted antitumor virotherapies [3] - The company utilizes proprietary technology to enhance the immune system's ability to fight cancer, specifically through stem cell-based platforms that carry oncolytic viruses [3] Recent Financial Activity - Calidi announced the closing of a public offering of 5,000,000 shares of common stock at a price of $0.85 per share, resulting in gross proceeds of approximately $4.25 million [1] - The offering was facilitated by Ladenburg Thalmann & Co. Inc. as the exclusive placement agent [1] Regulatory Information - The public offering was conducted under registration statements on Form S-3, which were declared effective by the SEC on October 10, 2024 [2] - A final prospectus related to the offering was filed with the SEC on January 10, 2025, and is available on the SEC's website [2]

Group 1 - Calidi Biotherapeutics, Inc. has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with expected gross proceeds of approximately $4.25 million before fees and expenses [1][2] - The offering is being conducted under a shelf registration statement declared effective by the SEC on October 10, 2024, and will be made only by means of a written prospectus [3] - The company intends to use the net proceeds from the offering for working capital and general corporate purposes [2] Group 2 - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted immunotherapies using proprietary technology that enhances the immune system's ability to fight cancer [5] - The company utilizes allogeneic stem cells to deliver oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors [5] - Calidi's dual approach aims to treat or prevent metastatic disease through its preclinical off-the-shelf enveloped virotherapies [5]

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 2834 Primary Standard Industrial Classification Code Number Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (IRS Employer Identification No.) Delaware 86-2967193 4475 Executive Drive, Suite 200 San Diego, CA 92121 (858) 794-9600 (Address, including zip code, and telepho ...

Core Viewpoint - Calidi Biotherapeutics Inc. has successfully closed a public offering of 4,437,869 shares at $1.69 per share, raising approximately $7.5 million in gross proceeds [1]. Group 1: Public Offering Details - The public offering was conducted under registration statements on Form S-3, which were declared effective by the SEC on October 10, 2024 [2]. - The final prospectus related to the offering was filed with the SEC on November 15, 2024, and is accessible on the SEC's website [2]. Group 2: Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted antitumor virotherapies using proprietary technology [3]. - The company utilizes allogeneic stem cells to deliver oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors [3]. - Calidi's platforms aim to enhance the efficacy and safety of oncolytic viruses, potentially treating or preventing metastatic disease [3].

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has priced its public offering of 4,437,869 shares of the Company’s common stock at a price of $1.69 per share. The closing of the offering is expected to occur on or about November 15, 2024, subject to the satisfaction of customary closing conditions. Ladenburg Thal ...

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company. Ladenburg Thalmann & Co. Inc. ...

Financial Performance - Calidi Biotherapeutics reported a net loss of $5.1 million, or $0.65 per share, for Q3 2024, compared to a net loss of $2.0 million, or $1.41 per share, for the same period in 2023[7]. - Research and development expenses decreased to $2.2 million in Q3 2024 from $3.3 million in Q3 2023[7]. - General and administrative expenses were $3.1 million for Q3 2024, down from $4.0 million in Q3 2023[8]. Funding and Financial Position - The company raised $2 million through a registered direct offering and concurrent private placement in October 2024[6]. - As of September 30, 2024, Calidi had approximately $1.9 million in cash and $0.2 million in restricted cash, consistent with December 31, 2023[8]. - Total current liabilities increased to $11.6 million as of September 30, 2024, compared to $10.2 million at the end of 2023[11]. - Total assets decreased to $6.7 million as of September 30, 2024, down from $10.0 million at the end of 2023[11]. - The accumulated deficit increased to $117.6 million as of September 30, 2024, compared to $99.6 million at the end of 2023[11]. Clinical Developments - The FDA cleared Northwestern University's IND application for Calidi's NeuroNova (CLD-101) clinical trial in high-grade glioma, expected to start in early 2025[4]. - Data on RTNova (CLD-400) was presented at multiple international conferences, highlighting its potential to target multiple tumor sites[5].

Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Diego, California.Raised $2 million in a registered direct offering and concurrent private placement. ...